Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis

Neurology

Volumn 65, Issue 7, 2005, Pages 1051-1056

  Nakamura, M ^a   Yamashita, T ^b   Ueda, M ^b   Obayashi, K ^c   Sato, T ^b   Ikeda, T ^b   Washimi, Y ^d   Hirai, T ^b   Kuwahara, Y ^b   Yamamoto, M T ^b   Uchino, M ^b   Ando, Yukio ^b  

^a NATIONAL INSTITUTE FOR MINAMATA DISEASE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c OITA UNIVERSITY   (Japan)

^d Department of Neurology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CYSTEINE; GADOLINIUM; PREALBUMIN; TYROSINE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOPSY; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BLOOD VESSEL WALL; BRAIN; BRAIN STEM; CLINICAL ARTICLE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DURA MATER; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; FOURIER TRANSFORMATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE RECONSTRUCTION; JAPAN; LEPTOMENINX; MALE; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULOLEPTOMENINGEAL AMYLOIDOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SPINAL CORD; STEADY STATE; SUBARACHNOID SPACE; SYMPTOM; THREE DIMENSIONAL IMAGING;

EID: 26444577075     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000178983.20975.af     Document Type: Article

References (26)

1. Araki S. Type I familial amyloidotic polyneuropathy (Japanese type). Brain Dev 1984;6:128-133.
2. Benson MD. Familial amyloidotic polyneuropathy. Trends Neurosci 1989;12:88-92.
3. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-184.
4. Goren H, Steinberg MC, Farboody GH. Familial oculoleptomeningeal amyloidosis. Brain 1980;103:473-495.
5. Uitti RJ, Donat JR, Rozdilsky B, Schneider RJ, Koeppen AH. Familial oculoleptomeningeal amyloidosis. Report of a new family with unusual features. Arch Neurol 1988;45:1118-1122.
6. Ushiyama M, Ikeda S, Yanagihara N. Transthyretin type cerebral amyloid angiopathy in type I familial amyloid polyneuropathy. Acta Neuropathol (Berl) 1991;81:524-528.
7. Kametani F, Ikeda S, Yanagisawa N, Ishi T, Hanyu N. Characterization of a transthyretin- related amyloid fibril protein from cerebral amyloid angiopathy in type I familial amyloid polyneuropathy. J Neurol Sci 1992;108:178-183.
8. Garzuly F, Wisniewski T, Brittig F, Budka H. Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). Neurology 1996;47:1562-1567.
9. Herrick MK, DeBruyne K, Horoupian DS, Skare J, Vanefsky MA, Ong T. Massive leptomeningeal amyloidosis associated with a Va130Met transthyretin gene. Neurology 1996;47:988-992.
10. Vidal R, Garzuly F, Budka H, et al. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD18G). Am J Pathol 1996;148:361-366.
11. Petersen RB, Goren H, Cohen M, et al. Transthyretin amyloidosis: a new mutation associated with dementia. Ann Neurol 1997;41:307-313.
12. Brett M, Persey MR, Reilly MM, et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain 1999;122:183-190.
13. Sakashita N, Ando Y, Jinnouchi K, et al. Familial amyloidotic polyneuropathy (ATTR Va130Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int 2001;51:476-480.
14. Blevins G, Macaulay R, Harder S, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 2003;60:1625-1630.
15. Ueno S, Fujimura H, Yorifuji S, et al. Familial amyloid polyneuropathy associated with the transthyretin Cys114 gene in a Japanese kindred. Brain 1992;115:1275-1289.
16. Haagsma EB, Post JG, De Jager AEJ, Nikkels PGJ, Hamel BCJ, Hazenberg BPC. A Dutch kindred with familial amyloidotic polyneuropathy associated with the transthyretin Cys 114 mutant. Amyloid 1997; 4:112-117.
17. Andersson M, Alvarez-Cermeno J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994;57:897-902.
18. Reiber H. CSF flow-its influence on CSF concentration of brain-derived proteins. In: Teelken A, Korf J, ed. Neurochemistry. New York: Plenum, 1997;51-72.
19. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001;310:173-186.
20. Shigematsu Y, Korogi Y, Hirai T, et al. Contrast-enhanced CISS MRI of vestibular schwannomas: phantom and clinical studies. J Comput Assist Tomogr 1999;23:224-231.
21. Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994;31:351-354.
22. Ohmori H, Ando Y, Makita Y, et al. Common origin of the Va130Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy. J Med Genet 2004;41:e51.
23. Murakami K, Irie K, Morimoto A, et al. Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. J Biol Chem 2003;278:46179-46187.
24. Eneqvist T, Olofsson A, Ando Y, et al. Disulfide-bond formation in the transthyretin mutant Y114C prevents amyloid fibril formation in vivo and in vitro. Biochemistry 2002;41:13143-13151.
25. Maeda A, Yamada M, Itoh Y, Otomo E, Hayakawa M, Miyatake T. Computer-assisted three-dimensional image analysis of cerebral amyloid angiopathy. Stroke 1993;24:1857-1864.
26. Bozzao A, Floris R, Fasoli F, et al. Cerebrospinal fluid changes after intravenous injection of gadolinium chelate: assessment by FLAIR MR imaging. Eur Radiol 2003;13:592-597.